BridgeBio Oncology Therapeutics, Inc (BBOT) vs Ocugen, Inc. (OCGN)
BridgeBio Oncology Therapeutics, Inc and Ocugen, Inc. are both Biotechnology companies. BridgeBio Oncology Therapeutics, Inc and Ocugen, Inc. are of similar size ($339.1M and $319.9M). BridgeBio Oncology Therapeutics, Inc has the higher net margin (0.00% vs −1,786.3%) and the lower return on invested capital (−127.7% vs 0.00%). Across the 12 metrics below, Ocugen, Inc. leads on 7 and BridgeBio Oncology Therapeutics, Inc on 5.
Valuation
Profitability
| Metric | BBOT | OCGN | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 100.00% | 65.16% |
| Operating margin | 0.00% | (1,504.43%) | 0.00% |
| Net margin | 0.00% | (1,786.27%) | 0.00% |
| Free cash flow margin | 0.00% | (1,332.36%) | 0.00% |
| Return on equity | (252.10%) | 1,211.66% | (57.72%) |
| Return on assets | (96.69%) | (92.03%) | (49.22%) |
| Return on invested capital | (127.66%) | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack